For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Denali Therapeutics Inc (NASDAQ: DNLI) closed the day trading at $14.01 down -4.17% from the previous closing price of $14.62. In other words, the price has decreased by -$4.17 from its previous closing price. On the day, 1.05 million shares were traded.
Ratios:
For a better understanding of DNLI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.56 and its Current Ratio is at 9.56. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is -1.20%, while the 200-Day Moving Average is calculated to be -32.74%.
Shares Statistics:
A total of 145.25M shares are outstanding, with a floating share count of 125.73M. Insiders hold about 13.46% of the company’s shares, while institutions hold 92.15% stake in the company.
